Public Act 097-0872 Public Act 0872 97TH GENERAL ASSEMBLY |
Public Act 097-0872 | HB5233 Enrolled | LRB097 20167 RPM 65645 b |
|
| AN ACT concerning public health.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Illinois Food, Drug and Cosmetic Act is | amended by changing Sections 2.4, 3.22, 5, and 6 as follows:
| (410 ILCS 620/2.4) (from Ch. 56 1/2, par. 502.4)
| Sec. 2.4.
(a) "Drug" means (1) articles recognized in the | official United
States Pharmacopoeia - National Formulary, | official Homeopathic Pharmacopoeia
of the United
States, | United States Dispensatory, or Remington's Practice of | Pharmacy,
or any supplement to any of them; and (2)
articles | intended for use in the diagnosis, cure, mitigation, treatment | or
prevention of disease in man or other animals; and (3) | articles (other than
food) intended to affect the structure or | any function of the body of man
or other animals; and (4) | articles intended for use as a component of any
article | specified in clause (1), (2) or (3); but does not include | devices
or their components, parts or accessories.
| (b) "Synthetic drug product" means any product that | contains a substance defined as a controlled substance under | subsections (d) and (e) of Section 204 of the Illinois | Controlled Substances Act. Products approved by the U.S. Food | and Drug Administration for human consumption are not synthetic |
| drug products. | (Source: P.A. 84-891.)
| (410 ILCS 620/3.22) (from Ch. 56 1/2, par. 503.22)
| Sec. 3.22.
(a) Whoever knowingly distributes, or possesses | with intent to
distribute, human growth hormone for any use in | humans other than the
treatment of a disease or other | recognized medical condition, where the use
has been authorized | by the Secretary of Health and Human Services and under
the | order of a physician, is guilty of a Class 3 felony, and may be | fined
an amount not to exceed $50,000. As used in this Section, | the term "human growth hormone" means somatrem, somatropin, or | an analogue of either of them.
| (b) Whoever distributes, or possesses with intent to | distribute, a synthetic drug product or a drug that is | misbranded under this Act is guilty of a Class 2 felony and may | be fined an amount not to exceed $100,000. A person convicted | of a second or subsequent violation of this Section is guilty | of a Class 1 felony, the fine for which shall not exceed | $250,000. | (c) Whoever falsely advertises a synthetic drug product is | guilty of a Class 3 felony and may be fined an amount not to | exceed $100,000. | (d) Whoever commits any offense set forth in this Section | and the offense
involves an individual under 18 years of age is | punishable by not more than
10 years imprisonment, and twice |
| the fine authorized above. Any conviction
for a violation of | this Section shall be considered a violation of the
Illinois | Controlled Substances Act for the purposes of forfeiture under
| Section 505 of such Act. As used in this Section the term | "human growth
hormone" means somatrem, somatropin, or an | analogue of either of them. The
Department of State Police and | Department of Professional Regulation are
authorized to | investigate offenses punishable by this Section.
| (e) Any person convicted under this Section is subject to | the forfeiture provisions set forth in subsections (c), (d), | (e), (f), (g), (h), and (i) of Section 3.23 of this Act. | (Source: P.A. 87-754.)
| (410 ILCS 620/5) (from Ch. 56 1/2, par. 505)
| Sec. 5.
(a) A person who violates any of the provisions of | this Act,
other than Sections 3.22 and 6, is guilty of a Class | C misdemeanor; but if
the violation is committed after a | conviction of such person under this
Section has become final, | the person shall be guilty of a Class A
misdemeanor. A person | who violates the provisions of Section 6 of this Act
is guilty | of a Class A misdemeanor; but if the violation is committed | after
a conviction of such person under this Section has become | final, the person
shall be guilty of a Class 4 felony.
| (b) No person is subject to the penalties of subsection (a) | of this
Section for (1) violating Section 3.1 or 3.3 if he | establishes a guaranty or
undertaking signed by and containing |
| the name and address of the person
residing in the State of | Illinois from whom he received the article in good
faith, to | the effect that the article is not adulterated or misbranded
| within the meaning of this Act, designating this Act; or (2) | for having
violated clause (2) of Section 3.16 if such person | acted in good faith and
had no reason to believe that the use | of the punch, die, plate, stone or
other thing involved would | result in a drug being a counterfeit drug, or
for having | violated clause (3) of Section 3.16 if the person doing the act
| or causing it to be done acted in good faith and had no reason | to believe
that the drug was a counterfeit drug.
| (c) No publisher, radio-broadcast licensee, agency or | medium for the
dissemination of an advertisement, except the | manufacturer, packer,
distributor or seller of the article to | which a false advertisement relates
is liable under this | Section for the dissemination of such false
advertisement | unless he has refused on the request of the Director to
furnish | the Director the name and post office address of the | manufacturer,
packer, distributor, seller or advertising | agency residing in the State of
Illinois who causes him to | disseminate such advertisement.
| (d) No person shall be subject to the penalties of | subsection (a) of
this Section for a violation of Section 3 | involving misbranded food if the
violation exists solely | because the food is misbranded under subsection
(c) of Section | 11 because of its advertising, and no person shall be
subject |
| to the penalties of subsection (a) of this Section for such a
| violation unless the violation is committed with the intent to | defraud
or mislead.
| (Source: P.A. 86-704; 87-754.)
| (410 ILCS 620/6) (from Ch. 56 1/2, par. 506)
| Sec. 6.
(a) When an authorized agent of the Director finds | or has probable
cause to believe that any food, drug, device or | cosmetic is adulterated or
so misbranded as to be dangerous or | fraudulent within the meaning of this
Act , or is in violation | of Section 12, 17 or 17.1 of this Act, or is suspected to be a | synthetic drug product, he or she
shall affix to such article a | tag or other appropriate marking
giving notice that the article | is or is suspected of being adulterated or
misbranded and has | been detained or embargoed and warning all persons not
to | remove or dispose of such article by sale or otherwise until | permission
for removal or disposal is given by such agent or | the court. It is unlawful
for any person to remove or dispose | of such detained or embargoed article
by sale or otherwise | without such permission.
| (b) When an article detained or embargoed under subsection | (a) of this
Section is found by such agent to be adulterated or | misbranded or to be
in violation of Section 12, 17 or 17.1 of | this Act or is suspected to be a synthetic drug product ,
he or | she shall petition the
circuit court in whose jurisdiction the | article is detained or embargoed
for a libel for condemnation |
| of such article. When such agent finds that an
article so | detained or embargoed is not adulterated or misbranded or is | not a synthetic drug product , he or
she shall remove the tag or | other marking.
| (c) If the court finds that a detained or embargoed article | is
adulterated or misbranded, such article shall, after entry | of the judgment, be
destroyed at the expense of the claimant | thereof, under the supervision
of such agent, and all court | costs and fees, and storage and other proper
expenses, shall be | taxed against the claimant of such article or his or her
agent. | However, when the adulteration or misbranding can be corrected | by proper
labeling or processing of the article, the court, | after entry of the judgment
and after such costs, fees and | expenses have been paid and a good and
sufficient bond, | conditioned that such article shall be so labeled or
processed, | has been executed, may by order direct that such article be
| delivered to the claimant thereof for such labeling or | processing under the
supervision of an agent of the Director. | The expense of such supervision
shall be paid by the claimant. | The article shall be returned to the claimant
and the bond | shall be discharged on the representation to the court by the
| Director that the article is no longer in violation of this | Act, and that
the expenses of such supervision have been paid.
| (d) Whenever the Director or any of his or her authorized | agents finds
in any room, building, vehicle of transportation | or other structure, any
meat, sea food, poultry, vegetable, |
| fruit or other perishable articles
which contain any filthy, | decomposed or putrid substance, or that may be
poisonous or | deleterious to health or otherwise unsafe, the same being
| hereby declared to be a nuisance, the Director or his or her | authorized
agent shall condemn or destroy the same, or in any | other manner render the
same unusable as human food.
| (Source: P.A. 85-564.)
| Section 10. The Illinois Controlled Substances Act is | amended by changing Section 204 as follows: | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | Sec. 204. (a) The controlled substances listed in this | Section are
included in Schedule I. | (b) Unless specifically excepted or unless listed in | another
schedule, any of the following opiates, including their | isomers,
esters, ethers, salts, and salts of isomers, esters, | and ethers,
whenever the existence of such isomers, esters, | ethers and salts is
possible within the specific chemical | designation: | (1) Acetylmethadol; | (1.1) Acetyl-alpha-methylfentanyl | (N-[1-(1-methyl-2-phenethyl)-
| 4-piperidinyl]-N-phenylacetamide); | (2) Allylprodine; | (3) Alphacetylmethadol, except
|
| levo-alphacetylmethadol (also known as levo-alpha-
| acetylmethadol, levomethadyl acetate, or LAAM); | (4) Alphameprodine; | (5) Alphamethadol; | (6) Alpha-methylfentanyl
| (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| propanilido) piperidine; | (6.1) Alpha-methylthiofentanyl
| (N-[1-methyl-2-(2-thienyl)ethyl-
| 4-piperidinyl]-N-phenylpropanamide); | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | (7.1) PEPAP
| (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | (8) Benzethidine; | (9) Betacetylmethadol; | (9.1) Beta-hydroxyfentanyl
| (N-[1-(2-hydroxy-2-phenethyl)-
| 4-piperidinyl]-N-phenylpropanamide); | (10) Betameprodine; | (11) Betamethadol; | (12) Betaprodine; | (13) Clonitazene; | (14) Dextromoramide; | (15) Diampromide; | (16) Diethylthiambutene; |
| (17) Difenoxin; | (18) Dimenoxadol; | (19) Dimepheptanol; | (20) Dimethylthiambutene; | (21) Dioxaphetylbutyrate; | (22) Dipipanone; | (23) Ethylmethylthiambutene; | (24) Etonitazene; | (25) Etoxeridine; | (26) Furethidine; | (27) Hydroxpethidine; | (28) Ketobemidone; | (29) Levomoramide; | (30) Levophenacylmorphan; | (31) 3-Methylfentanyl
| (N-[3-methyl-1-(2-phenylethyl)-
| 4-piperidyl]-N-phenylpropanamide); | (31.1) 3-Methylthiofentanyl
| (N-[(3-methyl-1-(2-thienyl)ethyl-
| 4-piperidinyl]-N-phenylpropanamide); | (32) Morpheridine; | (33) Noracymethadol; | (34) Norlevorphanol; | (35) Normethadone; | (36) Norpipanone; | (36.1) Para-fluorofentanyl
|
| (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 4-piperidinyl]propanamide); | (37) Phenadoxone; | (38) Phenampromide; | (39) Phenomorphan; | (40) Phenoperidine; | (41) Piritramide; | (42) Proheptazine; | (43) Properidine; | (44) Propiram; | (45) Racemoramide; | (45.1) Thiofentanyl
| (N-phenyl-N-[1-(2-thienyl)ethyl-
| 4-piperidinyl]-propanamide); | (46) Tilidine; | (47) Trimeperidine; | (48) Beta-hydroxy-3-methylfentanyl (other name:
| N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| N-phenylpropanamide). | (c) Unless specifically excepted or unless listed in | another
schedule, any of the following opium derivatives, its | salts, isomers
and salts of isomers, whenever the existence of | such salts, isomers and
salts of isomers is possible within the | specific chemical designation: | (1) Acetorphine; | (2) Acetyldihydrocodeine; |
| (3) Benzylmorphine; | (4) Codeine methylbromide; | (5) Codeine-N-Oxide; | (6) Cyprenorphine; | (7) Desomorphine; | (8) Diacetyldihydromorphine (Dihydroheroin); | (9) Dihydromorphine; | (10) Drotebanol; | (11) Etorphine (except hydrochloride salt); | (12) Heroin; | (13) Hydromorphinol; | (14) Methyldesorphine; | (15) Methyldihydromorphine; | (16) Morphine methylbromide; | (17) Morphine methylsulfonate; | (18) Morphine-N-Oxide; | (19) Myrophine; | (20) Nicocodeine; | (21) Nicomorphine; | (22) Normorphine; | (23) Pholcodine; | (24) Thebacon. | (d) Unless specifically excepted or unless listed in | another
schedule, any material, compound, mixture, or | preparation which contains
any quantity of the following | hallucinogenic substances, or which
contains any of its salts, |
| isomers and salts of isomers, whenever the
existence of such | salts, isomers, and salts of isomers is possible
within the | specific chemical designation (for the purposes of this
| paragraph only, the term "isomer" includes the optical, | position and
geometric isomers): | (1) 3,4-methylenedioxyamphetamine
| (alpha-methyl,3,4-methylenedioxyphenethylamine,
| methylenedioxyamphetamine, MDA); | (1.1) Alpha-ethyltryptamine
| (some trade or other names: etryptamine;
| MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 3-(2-aminobutyl)indole; a-ET; and AET); | (2) 3,4-methylenedioxymethamphetamine (MDMA); | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| (also known as: N-ethyl-alpha-methyl-
| 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| and MDEA); | (2.2) N-Benzylpiperazine (BZP); | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | (4) 3,4,5-trimethoxyamphetamine (TMA); | (5) (Blank); | (6) Diethyltryptamine (DET); | (7) Dimethyltryptamine (DMT); | (7.1) 5-Methoxy-diallyltryptamine; | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | (9) Ibogaine (some trade and other names:
|
| 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| indole; Tabernanthe iboga); | (10) Lysergic acid diethylamide; | (10.1) Salvinorin A; | (10.5) Salvia divinorum (meaning all parts of the plant | presently classified
botanically as Salvia divinorum, | whether growing or not, the
seeds thereof, any extract from | any part of that plant, and every compound,
manufacture, | salts, isomers, and salts of
isomers whenever the existence | of such salts, isomers, and salts of
isomers is possible | within the specific chemical designation, derivative, | mixture, or preparation of that plant, its
seeds or | extracts);
| (11) 3,4,5-trimethoxyphenethylamine (Mescaline); | (12) Peyote (meaning all parts of the plant presently | classified
botanically as Lophophora williamsii
Lemaire, | whether growing or not, the
seeds thereof, any extract from | any part of that plant, and every compound,
manufacture, | salts, derivative, mixture, or preparation of that plant, | its
seeds or extracts); | (13) N-ethyl-3-piperidyl benzilate (JB 318); | (14) N-methyl-3-piperidyl benzilate; | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| (also known as N-hydroxy-alpha-methyl-
| 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
| (15) Parahexyl; some trade or other names:
| 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| dibenzo (b,d) pyran; Synhexyl; | (16) Psilocybin; | (17) Psilocyn; | (18) Alpha-methyltryptamine (AMT); | (19) 2,5-dimethoxyamphetamine
| (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | (20) 4-bromo-2,5-dimethoxyamphetamine
| (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 4-bromo-2,5-DMA); | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| Some trade or other names: 2-(4-bromo-
| 2,5-dimethoxyphenyl)-1-aminoethane;
| alpha-desmethyl DOB, 2CB, Nexus; | (21) 4-methoxyamphetamine
| (4-methoxy-alpha-methylphenethylamine;
| paramethoxyamphetamine; PMA); | (22) (Blank); | (23) Ethylamine analog of phencyclidine.
| Some trade or other names:
| N-ethyl-1-phenylcyclohexylamine,
| (1-phenylcyclohexyl) ethylamine,
| N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | (24) Pyrrolidine analog of phencyclidine. Some trade | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
| PHP; | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; | (26) 2,5-dimethoxy-4-ethylamphetamine
| (another name: DOET); | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| (another name: TCPy); | (28) (Blank); | (29) Thiophene analog of phencyclidine (some trade
| or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 2-thienyl analog of phencyclidine; TPCP; TCP); | (30) Bufotenine (some trade or other names:
| 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 3-(2-dimethylaminoethyl)-5-indolol;
| 5-hydroxy-N,N-dimethyltryptamine;
| N,N-dimethylserotonin; mappine); | (31) 1-Pentyl-3-(1-naphthoyl)indole | Some trade or other names: JWH-018; | (32) 1-Butyl-3-(1-naphthoyl)indole | Some trade or other names: JWH-073; | (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- | (2-iodophenyl)methanone | Some trade or other names: AM-694; | (34) 2-[ ( 1R,3S)-3-hydroxycyclohexyl]-5- | (2-methyloctan-2-yl)phenol | Some trade or other names: CP 47,497 47, 497 | and its C6, C8 and C9 homologs; |
| (34.5) (33) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | (2-methyloctan-2-yl)phenol), where side chain n=5; | and homologues where side chain n=4, 6, or 7; Some | trade or other names: CP 47,497; | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | (2-methyloctan-2-yl)-6a,7, | 10,10a-tetrahydrobenzo[c]chromen-1-ol | Some trade or other names: HU-210; | (35.5) (34) (6aS,10aS)-9-(hydroxymethyl)-6,6- | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | tetrahydrobenzo[c]chromen-1-ol, its isomers, | salts, and salts of isomers; Some trade or other | names: HU-210, Dexanabinol; | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | 6,6-dimethyl-3-(2-methyloctan-2-yl)- | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | Some trade or other names: HU-211; | (37) (2-methyl-1-propyl-1H-indol- | 3-yl)-1-naphthalenyl-methanone | Some trade or other names: JWH-015; | (38) 4-methoxynaphthalen-1-yl- | (1-pentylindol-3-yl)methanone | Some trade or other names: JWH-081; | (39) ( 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | Some trade or other names: JWH-122; | (40) 2-(2-methylphenyl)-1-(1-pentyl- |
| 1H-indol-3-yl)-ethanone | Some trade or other names: JWH-251; | (41) 1-(2-cyclohexylethyl)-3- | (2-methoxyphenylacetyl)indole | Some trade or other names: RCS-8, BTW-8 and SR-18 ; . | (42) (33) Any compound structurally derived from | 3-(1-naphthoyl)indole or 1H-indol-3-yl- | (1-naphthyl)methane by substitution at the | nitrogen atom of the indole ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl or | 2-(4-morpholinyl)ethyl whether or not further | substituted in the indole ring to any extent, whether | or not substituted in the naphthyl ring to any extent; | (43) (34) Any compound structurally derived from | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | cycloalkylmethyl, cycloalkylethyl or | 2-(4-morpholinyl)ethyl, whether or not further | substituted in the pyrrole ring to any extent, whether | or not substituted in the naphthyl ring to any extent; | (44) (35) Any compound structurally derived from | 1-(1-naphthylmethyl)indene by substitution | at the 3-position of the indene ring by alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl or | 2-(4-morpholinyl)ethyl whether or not further | substituted in the indene ring to any extent, whether |
| or not substituted in the naphthyl ring to any extent; | (45) (36) Any compound structurally derived from | 3-phenylacetylindole by substitution at the | nitrogen atom of the indole ring with alkyl, haloalkyl, | alkenyl, cycloalkylmethyl, cycloalkylethyl or | 2-(4-morpholinyl)ethyl, whether or not further | substituted in the indole ring to any extent, whether | or not substituted in the phenyl ring to any extent; | (46) (37) Any compound structurally derived from | 2-(3-hydroxycyclohexyl)phenol by substitution | at the 5-position of the phenolic ring by alkyl, | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl | or 2-(4-morpholinyl)ethyl, whether or not substituted | in the cyclohexyl ring to any extent ; . | (47) (33) 3,4-Methylenedioxymethcathinone | Some trade or other names: Methylone; | (48) (34) 3,4-Methyenedioxypyrovalerone | Some trade or other names: MDPV; | (49) (35) 4-Methylmethcathinone | Some trade or other names: Mephedrone; | (50) (36) 4-methoxymethcathinone; | (51) (37) 4-Fluoromethcathinone; | (52) (38) 3-Fluoromethcathinone ; . | (53) (35) 2,5-Dimethoxy-4-(n)-propylthio- | phenethylamine; | (54) (36) 5-Methoxy-N,N-diisopropyltryptamine ; . |
| (55) Pentedrone. | (e) Unless specifically excepted or unless listed in | another
schedule, any material, compound, mixture, or | preparation which contains
any quantity of the following | substances having a depressant effect on
the central nervous | system, including its salts, isomers, and salts of
isomers | whenever the existence of such salts, isomers, and salts of
| isomers is possible within the specific chemical designation: | (1) mecloqualone; | (2) methaqualone; and | (3) gamma hydroxybutyric acid. | (f) Unless specifically excepted or unless listed in | another schedule,
any material, compound, mixture, or | preparation which contains any quantity
of the following | substances having a stimulant effect on the central nervous
| system, including its salts, isomers, and salts of isomers: | (1) Fenethylline; | (2) N-ethylamphetamine; | (3) Aminorex (some other names:
| 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| salts, optical isomers, and salts of optical isomers; | (4) Methcathinone (some other names:
| 2-methylamino-1-phenylpropan-1-one;
| Ephedrone; 2-(methylamino)-propiophenone;
| alpha-(methylamino)propiophenone; N-methylcathinone;
|
| methycathinone; Monomethylpropion; UR 1431) and its
| salts, optical isomers, and salts of optical isomers; | (5) Cathinone (some trade or other names:
| 2-aminopropiophenone; alpha-aminopropiophenone;
| 2-amino-1-phenyl-propanone; norephedrone); | (6) N,N-dimethylamphetamine (also known as:
| N,N-alpha-trimethyl-benzeneethanamine;
| N,N-alpha-trimethylphenethylamine); | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | (8) 3,4-Methylenedioxypyrovalerone (MDPV). | (g) Temporary listing of substances subject to emergency | scheduling.
Any material, compound, mixture, or preparation | that contains any quantity
of the following substances: | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| (benzylfentanyl), its optical isomers, isomers, salts,
| and salts of isomers; | (2) N-[1(2-thienyl)
| methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| its optical isomers, salts, and salts of isomers. | (Source: P.A. 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11; | 97-192, eff. 7-22-11; 97-193, eff. 1-1-12; 97-194, eff. | 7-22-11; 97-334, eff. 1-1-12; revised 9-14-11.)
| Section 15. The Drug Paraphernalia Control Act is amended | by changing Section 2 as follows:
|
| (720 ILCS 600/2) (from Ch. 56 1/2, par. 2102)
| Sec. 2. As used in this Act, unless the context otherwise | requires:
| (a) The term "cannabis" shall have the meaning ascribed to | it in Section
3 of the Cannabis Control Act, as if that | definition were incorporated
herein.
| (b) The term "controlled substance" shall have the meaning | ascribed to
it in Section 102 of the Illinois Controlled | Substances Act, as if that
definition were incorporated herein.
| (c) "Deliver" or "delivery" means the actual, constructive | or attempted
transfer of possession, with or without | consideration, whether or not there
is an agency relationship.
| (d) "Drug paraphernalia" means all equipment, products and | materials of
any kind, other than methamphetamine | manufacturing materials as defined in Section 10 of the | Methamphetamine Control and Community Protection Act, which | are intended to be used unlawfully in planting, propagating,
| cultivating, growing, harvesting, manufacturing, compounding,
| converting, producing, processing, preparing, testing, | analyzing, packaging,
repackaging, storing, containing, | concealing, injecting, ingesting, inhaling
or otherwise | introducing into the human body cannabis or a controlled | substance
in violation of the Cannabis Control Act, the | Illinois Controlled
Substances
Act, or the Methamphetamine | Control and Community Protection Act or a synthetic drug |
| product or misbranded drug in violation of the Illinois Food, | Drug and Cosmetic Act . It
includes, but is not limited to:
| (1) kits intended to be used unlawfully in | manufacturing, compounding,
converting,
producing, | processing or preparing cannabis or a controlled | substance;
| (2) isomerization devices intended to be used | unlawfully in increasing
the potency of any species of | plant which is cannabis or a controlled
substance;
| (3) testing equipment intended to be used unlawfully in | a private home for
identifying
or in analyzing the | strength, effectiveness or purity of cannabis or | controlled
substances;
| (4) diluents and adulterants intended to be used | unlawfully for cutting
cannabis
or a controlled substance | by private persons;
| (5) objects intended to be used unlawfully in | ingesting, inhaling,
or otherwise introducing cannabis, | cocaine, hashish, or hashish oil , or a synthetic drug | product or misbranded drug in violation of the Illinois | Food, Drug and Cosmetic Act into
the human body including, | where applicable, the following items:
| (A) water pipes;
| (B) carburetion tubes and devices;
| (C) smoking and carburetion masks;
| (D) miniature cocaine spoons and cocaine vials;
|
| (E) carburetor pipes;
| (F) electric pipes;
| (G) air-driven pipes;
| (H) chillums;
| (I) bongs;
| (J) ice pipes or chillers;
| (6) any item whose purpose, as announced or described | by the seller, is
for use in violation of this Act.
| (Source: P.A. 93-526, eff. 8-12-03; 94-556, eff. 9-11-05 .)
| Section 99. Effective date. This Act takes effect upon | becoming law. |
Effective Date: 7/31/2012
|